keyword
MENU ▼
Read by QxMD icon Read
search

Paritaprevir

keyword
https://www.readbyqxmd.com/read/28090038/combination-therapy-with-ombitasvir-paritaprevir-ritonavir-for-dialysis-patients-infected-with-hepatitis-c-virus-a-prospective-multi-institutional-study
#1
Ken Sato, Kenichi Hosonuma, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Hiroshi Ohnishi, Hiroaki Okamoto, Masanobu Yamada
Hepatitis C virus (HCV) infection is common in dialysis patients worldwide and nosocomial HCV spread within dialysis facilities continues to develop. Combination therapy with daclatasvir and asunaprevir (DCV/ASV) that has proven efficacy for dialysis patients infected with genotype 1b HCV (HCV/1b) has several concerns in Japan. The recently available combination therapy with ombitasvir, paritaprevir, and ritonavir (OBV/PTV/r) is not contraindicated in patients with chronic renal failure and has more safety profile and shorter treatment period than that with DCV/ASV...
2017: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28052633/hepatitis-c-efficacy-and-safety-in-real-life
#2
REVIEW
Robert Flisiak, Joanna Pogorzelska, Marta Flisiak-Jackiewicz
Interferon-free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real-world experience has been gathered in the last year and this paper presents data available in September 2016. Real-world studies on the efficacy of the ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR rate in the 13858 patients included in this paper was 94%, and 92% in the 3506 patients with cirrhosis...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28025084/a-profiling-study-of-a-newly-developed-hcvcc-strain-pr63cc-s-sensitivity-to-direct-acting-antivirals
#3
Wanyin Tao, Tianyu Gan, Jie Lu, Jin Zhong
The development of direct-acting antivirals (DAAs) has significantly improved hepatitis C virus (HCV) treatment. However, drug resistance remains a potential concern in the real-world DAA-based therapies. We previously developed a novel full-length genotype 2a HCVcc clone PR63cc directly from clinical isolates. Here in this study, we compared the sensitivity of PR63cc and JFH1 to 12 different DAAs most of which are either already in clinical use or in the late clinical development phase. For NS5B inhibitors, PR63cc and JFH1 displayed comparable sensitivity to nucleoside/nucleotide analogues sofosbuvir and 2'-C-methyladenosine, while PR63cc was 4-fold more sensitive than JFH1 to nesbuvir, a non-nucleoside inhibitor...
December 23, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28018873/restrictions-for-reimbursement-of-direct-acting-antiviral-treatment-for-hepatitis-c-virus-infection-in-canada-a-descriptive-study
#4
Alison D Marshall, Sahar Saeed, Lisa Barrett, Curtis L Cooper, Carla Treloar, Julie Bruneau, Jordan J Feld, Lesley Gallagher, Marina B Klein, Mel Krajden, Naglaa H Shoukry, Lynn E Taylor, Jason Grebely
BACKGROUND: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4 HCV direct-acting antivirals in Canada. METHODS: We reviewed the reimbursement criteria for simeprevir, sofosbuvir, ledipasvir-sofosbuvir and paritaprevir-ritonavir-ombitasvir plus dasabuvir in the 10 provinces and 3 territories...
October 2016: CMAJ Open
https://www.readbyqxmd.com/read/28011605/ombitasvir-paritaprevir-ritonavir-and-dasabuvir-combination-treatment-in-patients-with-hiv-hcv-co-infection-results-of-an-italian-compassionate-use-program
#5
Andreoni Massimo, Elisabetta Teti, Andrea Antinori, Laura Milazzoi, Savatore Sollima, Giuliano Rizzardini, Antonio Di Biagio, Annalisa Saracino, Raffaele Bruno, Vanni Borghi, Andrea De Luca, Annamaria Cattelan, Hamid Hasson, Gloria Taliani, Antonella D'Arminio Monforte, Claudio Maria Mastroianni, Giovanni Di Perri, Sara Bigoni, Massimo Puoti, Angiola Spinetti, Andrea Gori, Nicola Boffa, Cacopardo Bruno, Andrea Giacometti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Alfredo Pennica, Caterina Pasquazzi, Daniela Segala, Loredana Sarmati
Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).
December 22, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27981315/a-case-of-acute-liver-failure-during-ritonavir-boosted-paritaprevir-ombitasvir-and-dasabuvir-therapy-in-a-patient-with-hcv-genotype-1b-cirrhosis
#6
Marco Masetti, Donatella Magalotti, Elena Martino, Pietro Andreone, Alessandra Scuteri, Marco Zoli
BACKGROUND: Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin is one of the current recommended therapies for HCV genotype 1b monoinfected patients in compensated (Child-Pugh A) cirrhosis. Whether it is known that the worsening of liver function is a rare but possible complication of Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir therapy, to our knowledge no description of treatment-related acute liver failure is available in the literature. CASE PRESENTATION: An 84-year-old Caucasian man with chronic compensated HCV genotype 1b cirrhosis received Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy...
December 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/27976491/effectiveness-and-safety-of-ombitasvir-paritaprevir-ritonavir-%C3%A2-dasabuvir-%C3%A2-ribavirin-an-early-access-programme-for-spanish-patients-with-genotype-1-4-chronic-hepatitis-c-virus-infection
#7
C Perelló, J A Carrión, B Ruiz-Antorán, J Crespo, J Turnes, J Llaneras, S Lens, M Delgado, J García-Samaniego, F García-Paredes, I Fernández, R M Morillas, D Rincón, J C Porres, M Prieto, M Lázaro Ríos, C Fernández-Rodríguez, J A Hermo, M Rodríguez, J I Herrero, P Ruiz, J R Fernández, M Macías, J M Pascasio, J M Moreno, M Á Serra, J Arenas, Y Real, F Jorquera, J L Calleja
Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naïve and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27976490/therapy-with-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-is-effective-and-safe-for-the-treatment-of-genotype-1-and-4-hepatitis-c-virus-infection-hcv-in-patients-with-severe-renal-impairment-a-multicenter-experience
#8
Raquel Muñoz-Gómez, Diego Rincón, Adriana Ahumada, Eduardo Hernández, María José Devesa, Sonia Izquierdo, Maria Ortiz, Alicia Hernández-Albujar, Conrado Fernández-Rodríguez, Marta Calvo, Rosario González, Mar Lozano, Gregorio Castellano, Inmaculada Fernández-Vázquez
Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15-29 mL/min/1...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27971346/the-benefits-of-earlier-treatment-with-paritaprevir-rotanavir-ombitasvir-with-or-without-dasabuvir-in-ireland
#9
R Baj, J Kavanagh, M O'Meara, C McKinley
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971322/health-economic-evaluation-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-for-treatment-of-chronic-genotype-1-hcv-infection-in-germany
#10
G Sroczynski, A Conrads-Frank, F Kühne, N Mühlberger, H Fröhlich, B Dietz, J C Samp, S Zeuzem, U Siebert
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971320/cost-effectiveness-of-paritaprevir-rotanavir-ombitasvir-with-or-without-dasabuvir-in-ireland
#11
R Baj, J Kavanagh, K M Egan, C McKinley
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970798/cost-effectiveness-of-ombitasvir-paritaprevir-ritonavir-with-or-without-dasabuvir-for-the-treatment-of-chronic-hepatitis-c-patients-infected-with-genotype-1-or-4-in-france
#12
G Sroczynski, A Conrads-Frank, N Mühlberger, F Kühne, G Jeanblanc, J C Samp, I Durand-Zaleski, U Siebert
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970795/cost-effectiveness-analysis-of-daclatasvir-with-asunaprevir-vs-paritaprevir-ritonavir-ombitasvir-with-dasabuvir-in-treatment-of-chronic-hepatitis-c-in-the-russian-federation
#13
R Yagudina, A Kulikov, V V Babiy
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27943605/efficacy-and-safety-of-direct-acting-antivirals-based-antiviral-therapies-for-hepatitis-c-virus-patients-with-stage-4-5-chronic-kidney-disease-a-meta-analysis
#14
Tao Li, Yundong Qu, Ying Guo, Yan Wang, Lei Wang
BACKGROUND & AIMS: The aim of this study was to assess the efficacy and safety of direct-acting antivirals (DAA)-based antiviral therapies for HCV patients with stage 4-5 chronic kidney disease. METHODS: We conducted a systematic literature search in PubMed, EMBASE, Web of Science, and CENTRAL on the Cochrane Library without time and language limitations. The search strategy used was "(End stage renal disease OR chronic kidney failure OR severe renal impairment OR chronic kidney disease OR dialysis) AND (sofosbuvir OR simeprevir OR grazoprevir OR elbasvir OR ombitasvir OR paritaprevir OR ritonavir OR dasabuvir OR daclatasvir OR asuparevir OR direct-acting antiviral OR DAA)"...
December 10, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27935166/time-to-viral-suppression-is-not-related-to-achievement-of-svr12-in-hcv-gt1-infected-patients-treated-with-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-with-or-without-ribavirin
#15
S Alqahtani, R Ozaras, V Isakov, D Wyles, P Ferenci, J J Feld, F Calinas, M Gschwantler, E Gane, D Crawford, I M Jacobson, E O Dumas, M King, M Sulkowski
High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12...
December 9, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27934775/real-world-effectiveness-and-predictors-of-sustained-virological-response-with-all-oral-therapy-in-21-242-hepatitis-c-genotype-1-patients
#16
Lisa I Backus, Pamela S Belperio, Troy A Shahoumian, Timothy P Loomis, Larry A Mole
BACKGROUND: Predictors of SVR to all-oral hepatitis C virus (HCV) regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir±ribavirin (LDV/SOF±RBV) and ombitasvir/paritaprevir/ritonavir+dasabuvir (OPrD)±RBV in patients treated in routine practice. METHODS: Observational, intent-to-treat cohort of 21,142 genotype 1 patients initiating 8 or 12 weeks of LDV/SOF±RBV or 12 weeks of OPrD±RBV at any Veterans Affairs facility...
December 9, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27932113/hepatitis-c-treatment-with-direct-acting-antivirals-in-kidney-transplant-preliminary-results-from-a-multicenter-study
#17
M A Gentil, C González-Corvillo, M Perelló, S Zarraga, C Jiménez-Martín, L R Lauzurica, A Alonso, A Franco, D Hernández-Marrero, A Sánchez-Fructuoso
Hepatitis C (HC) is a very relevant negative prognosis factor for graft and transplant recipient survival. New direct-acting antivirals (DAAs) allow us to solve this problem in an effective way. It is crucial to understand their real impact in our daily practice. We analyzed treatment results with DAA, free of interferon, in kidney transplant recipients (KTRs) from 15 Spanish hospitals (Grupo Español de Actualización en Trasplante), regarding effectiveness, tolerance, and impact on immunosuppression, renal function-proteinuria, and diabetes...
November 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27925355/epigenetic-analysis-of-the-ifn%C3%AE-3-gene-identifies-a-novel-marker-for-response-to-therapy-in-hcv-infected-subjects
#18
J F Waring, J W Davis, E Dumas, D Cohen, K Idler, S Abel, R Georgantas, T Podsadecki, S Dutta
Chronic hepatitis C virus (HCV) infection is characterized by high interindividual variability in response to pegylated interferon and ribavirin. A genetic polymorphism on chromosome 19 (rs12979860) upstream of interferon-λ3 (IFNλ3) is associated with a twofold change in sustained virologic response rate after 48 weeks of treatment with pegylated interferon/ribavirin in HCV genotype 1 (GT1) treatment-naïve patients. We conducted epigenetic analysis on the IFNλ3 promoter to investigate whether DNA methylation is associated with response to HCV therapy...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27919899/pharmacokinetic-evaluation-of-darunavir-administered-once-or-twice-daily-in-combination-with-ritonavir-or-the-three-direct-acting-antiviral-regimen-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-in-adults-co-infected-with-hepatitis-c-and-human-immunodeficiency
#19
Jennifer R King, Amit Khatri, Roger Trinh, Rolando M Viani, Bifeng Ding, Jiuhong Zha, Rajeev Menon
BACKGROUND: The three-direct acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir and dasabuvir ± ribavirin (RBV) is approved for treatment of HCV GT1/HIV-1 co-infection. Results of a pharmacokinetic substudy of 3D and darunavir are presented. METHODS: HCV/HIV-1 infected subjects were randomized to maintain a darunavir 800 mg once daily (QD) or switch to a darunavir 600 mg twice daily (BID) based antiretroviral regimen. On Study Day 1, subjects received 3D and RBV plus darunavir for 12 weeks...
December 5, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27914803/effectiveness-of-direct-acting-antivirals-in-hepatitis-c-virus-infection-in-haemodialysis-patients
#20
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás Macías, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection. Treatment with interferon and ribavirin is poorly tolerated and there are limited data on the experience with new direct-acting antivirals (DAAs). The aim of this study is to retrospectively analyse the current prevalence of HCV infection and efficacy and safety results with different DAA regimens in the haemodialysis population of 2hospital areas...
November 30, 2016: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
keyword
keyword
59050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"